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864-2 One-Year Follow-Up of Transendocardial Injection of 
Autologous Bone Marrow Mononuclear Cells for 
Ischemic Cardiomyopathy
Emerson C. Perin, Hans F. Dohmann, Radovan Borojevic, Suzana A. Silva, Andre L. 
Sousa, Guilherme V. Silva, Joao A. Assad, Claudio T. Mesquita, Luciano Belem, Roberto 
Esporcatte, Fernando O. Rangel, Antonio C. Carvalho, Isabel Rossi, William K. Vaughn, 
Hans J. Dohmann, James T. Willerson, Texas Heart Institue, Houston, TX, Pro-Cardiaco 
Hospital, Rio de Janeiro, Brazil
Background: Limited treatment options exist for patients with end-stage ischemic heart
failure (HF) not amenable to revascularization. We evaluated the effect of transendocar-
dial (TE) delivery of Autologous Bone Marrow Mononuclear Cells (ABMMC) in patients
with severe HF.
Methods: Ten patients (mean age 58 ± 11 yrs) were studied. All patients had LV dysfunc-
tion secondary to ischemic cardiomyopathy. Bone marrow (50 ml) was aspirated and
ABMMCs were isolated. TE injections were performed using the Myo-star catheter
(NOGA, Biosense) to target hibernating myocardium guided electromechanical mapping
(EMM). Patients were evaluated by ramp treadmill and Holter monitoring at baseline, 2
months , 6 months and one year. ANOVA was utilized.
Results: Exercise testing showed gradual and continous improvement in METs
(p=0.0005) and VO2max (p=0.002) over time . MET's improved from 4.9 at baseline to
6.7 at 2 months to 7.4 at 6 months up to 7.9 at one year follow-up. There was no differ-
ence in total number of PVC's over the follow-up period. Ramp treadmill findings of
VO2max are presented in figure 1.
Conclusion: In this small number of patients receiving TE injection of ABMMC and fol-
lowed up to one year there was no evidence of significant arrhythmias and there was sus-
tained improvement in exercise capacity. Future studies are needed to further clarify the
role of stem-cell therapy in the treatment of ischemic cardiomyopathy. 
9:00 a.m.
864-3 Transendocardial Autologous Bone Marrow Cell 
Transplantation in Patients With Advanced Ischemic 
Heart Disease: Final Results From a Multi-center 
Feasibility Study
Shmuel Fuchs, Ran Kornowski, Giora Weisz, Lowell F. Satler, Peter C. Smits, Petros 
Okubagzi, Ron Waksman, Neil J. Weissman, Manuel Cerqueira, Alexander Batler, 
Jeffrey W. Moses, Patrick W. Serruys, Martin B. Leon, Stephen E. Epstein, Washington 
Hospital Center, Washington, DC
Background—Experimental and initial clinical data suggest that intra-myocardial injec-
tion of autologous bone marrow (ABM) may improve myocardial perfusion in pts with
obstructive CAD. We therefore conducted a phase I study evaluating the feasibility, safety
and potential efficacy of such a strategy in "no-option" patients with refractory angina and
myocardial ischemia. Methods and Results—Twenty seven pts (58±9 yrs, 22 males, 12
diabetics, 18 with prior MI, 25 post CABG) received evenly distributed 12 transendomyo-
cardial injections (0.2 ml each) of freshly aspirated unfractionated ABM via electrome-
chanical mapping-guided injection catheter. Injected regions encompassed 18.9±6.9% of
total endocardial surface area. Pts were injected with 27±29x106/ml nucleated cells (lym-
phocytes 16.7±7.7%, monocytes fraction 3.9±1.2%, CD34+ 2.2±1.4%, CD34+/CD117+
85.8±12.2% of the total CD34+) directed into pre-defined ischemic myocardium. Proce-
dural success was 100%; mean mapping and injection time was 30±15 and 25±12 min,
respectively. ABM injection was associated with no adverse events. One cultured BM was
found contaminated but without clinical sequelae. At 3-month follow-up, 4 pts were read-
mitted for recurrent chest pain. CCS angina score significantly improved (3.2±0.5 vs.
2.0±0.91, P=0.001) as did frequency of angina (23±22 vs. 40±28, P=0.04) and quality of
life scores (26±16 vs. 44±28, P=0.03).Serial echocardiography showed no deterioration
in segmental or global LV function. Treadmill exercise duration significantly improved
(417±136 vs. 488±206 sec, P=0.05). Stress-induced ischemia within the injected territo-
ries (113 segments) improved (2.2±0.8 vs. 1.7±1.1, P<0.001). At 1-year, clinical
response available in 16 patients was sustained. Complete data will be presented at the
time of the meeting. Conclusions—This feasibility study provides clinical data indicating
safety of catheter-based transendocardial delivery of ABM in patients with advanced
symptomatic ischemic heart disease. The results also suggest potential efficacy, under-
scoring the advisability for further evaluation.
9:15 a.m.
864-4 Investigating Platelet Activation With Abciximab and 
High-Dose Tirofiban in Patients With Acute Myocardial 
Infarction Undergoing Primary Percutaneous Coronary 
Intervention
Jochem W. van Werkum, Wim B M Gerritsen, Hans C. Kelder, Fred JLM Haas, Maarten-
Jan Suttorp, Egbert T. Bal, Benno JWM Rensing, Sjef MPG Ernst, Jurriën M. ten Berg, 
Sint Antonius Hospital, Nieuwegein, The Netherlands
Background
Glycoprotein IIb/IIIa (GP IIb/IIIa) antagonists have shown to reduce thrombotic complica-
tions in patients undergoing elective percutaneous coronary intervention (PCI). In
patients with acute myocardial infarction (AMI) however, there is only few data on the
amount and duration of platelet activation. In addition, new data suggest that the dose of
tirofiban used in previous studies was too low. The present study investigated platelet
activation in AMI patients undergoing PCI as well as the effects of abciximab and a
higher-dose of tirofiban.
Methods
We prospectively randomised 60 AMI patients to abciximab (N=20; bolus 25 mg/kg, than
12-hours 0,125 mg/kg/min), to high-dose tirofiban (N=20; bolus 25 µg/kg, than 18 hours
0,15 µg/kg/min i.v) or to no addition treatment (N=20). Platelet activation (CD62p and
CD14 positive platelets) and GP IIb/IIIa receptor occupancy (Biotex GP IIb/IIIa receptor
occupancy kit) was measured by flow cytometry at 5 timepoints: before(t=0), immediately
after(t=1), 30 min (t=2), 60 min(t=3) and 120 min (t=4) after PCI. Analysis was done by
repeated measures using ANOVA.
Results
The number of activated platelets in the treated groups were significantly lower than in
the control group (p<0.0001). Abciximab resulted in a significantly higher GP IIb/IIIa
receptor-occupancy than high-dose tirofiban (figure, p<0.0001).
conclusion
Despite an increased high-dose regimen, tirofiban leads to significantly lower platelet
inhibition than abciximab in AMI patients.
9:30 a.m.
864-5 Effects of Prolonged Oral Simvastatin Treatment After 
Coronary Stenting on Neointimal Growth and Plaque 
Progression as Assessed by Intravascular Ultrasound: 
A Randomized Study
Giovanni Amoroso, Anna Sonia Petronio, Barbara Papini, Andrea Micheli, Ugo Limbruno, 
Marco De Carlo, Nicola Ciabatti, Mario Mariani, University of Pisa, Pisa, Italy
BACKGROUND: Statins have proven to reduce adverse events, but not in-stent resteno-
sis (ISR) and plaque progression after coronary stenting.
METHODS: 71 normocholesterolemic consecutive patients with stable angina and a sin-
gle native de-novo lesion suitable for percutaneous intervention, were randomized to sim-
vastatin (S) (20 mg/daily) or placebo (P) 2 weeks before, and continuing for 12 months
after successful coronary stenting. Exclusion criteria were: acute coronary syndromes,
diabetes, ongoing statin treatment. End-points were binary ISR, neointimal growth, and
plaque progression, both at stented and non-stented sites, as assessed by intravascular
ultrasound (IVUS), at 12-month follow-up, major cardiovascular events (MACE).
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RESULTS: 69 patients (98% of total) completed a 12-months clinical follow up. MACE
were: S: 4/36 (11%) and P: 8/33 (24%)(p<0.05). 61 patients (85%) had repeat catheter-
ization at 11±7 months. Binary ISR was: S: 5/33 (14%) and P: 5/28 (18%)(p:NS). Minimal
lumen area was: S: 5.7±1.4 and P: 6.1±2.2 mm² (p::NS); neointimal volume index
(=[stent-lumen volume]/stent length) was: S: 3.6±1.8 and P: 3.8±2.3 mm³/mm (p:NS);
obstruction volume percent (=[stent-lumen volume]/stent volume%) was: S: 34±15 and
P: 35±23% (p:NS). External plaque percent (=[vessel-stent volume]/vessel volume%) at
stented site, at baseline and follow-up, was S: 53±10 and 39±9%, and P: 51±12 and
57±11% (p<0.05). External plaque volume index (=[vessel-stent volume]/stent length), at
baseline and follow-up, was: S: 11.9±4.2 and 7.9±3.3 mm³/mm, and P: 10.9±4.0 and
11.6±3.5 mm³/mm (p<0.05). Total plaque percent (=[vessel-lumen volume]/vessel vol-
ume%) at non-stented sites, at baseline and follow-up, was: S: 49±8 and 39±7%, and P:
47±8 and 56±10% (p<0.05). Total plaque volume index (=[vessel-lumen volume]/seg-
ment length), at baseline and follow-up, was: S: 9.8±3.6 and 7.3±2.5 mm³/mm, and P:
8.8±2.9 and 9.8±3.1 mm³/mm (p<0.05).
CONCLUSION: In normocholesterolemic patients, prolonged treatment with oral simvas-
tatin shows no effect in preventing ISR and neointimal growth after coronary stenting.
However, it reduces MACE and induces a diffuse regression of the atherosclerotic plaque
burden.
9:45 a.m.
864-6 Prolonged Clopidogrel Treatment Reduces Lesion Cell 
Proliferation After Balloon Injury and Intracoronary 
Radiation
Klaus Pels, Carolin Deiner, Ursula Rauch, Christoph Loddenkemper, Peter Lothar 
Schwimmbeck, Charite-University Medicine Berlin, Campus Benjamin Franklin, Berlin, 
Germany
BACKGROUND: Prolonged Clopidogrel therapy after intracoronary radiation (IR) treating
in-stent restenosis has been shown to reduce major adverse clinical events (MACE). This
beneficial effect has been mainly contributed to the antithrombotic mechanism, but it is
unknown whether the P2Y12 receptor antagonist mediates additional effects preventing
MACE. The purpose of our study was to analyze the effect of prolonged Clopidogrel
treatment on cell proliferation in the intimal/medial vascular lesion (I+M VL) of balloon-
injured coronary arteries with or without beta-IR. METHODS: 24 porcine coronary arter-
ies were subjected to balloon injury (PTCA) of which 12 arteries underwent immediate
ionizing radiation using a source train of 90S/Y seeds delivering 20 Gy at a depth of 2
mm from the source. Animals were divided into two groups, one group receiving 4 weeks
Clopidogrel treatment (28dCl) and the second 3 months (90dCl). Bromo-deoxyuridine
was administered one hour prior to euthanasia to label proliferating cells. Coronary arter-
ies were immunohistochemically examined 3 months after injury. RESULTS: Cell prolifer-
ation in the I+M VL of the 90dCl group was significantly reduced in comparison to the
28dCl group (PTCA+IR:18.40 ± 2.17 proliferating cells/mm² in the 90dCl group vs.
101.81 ± 5.99 in the 28dCl group, P<0.001; PTCA: 16.2 ± 6.55 proliferating cells/mm² in
the 90dCl group vs. 209.21 ± 23.51 in the 28dCl group, P<0.05). CONCLUSION: Pro-
longed Clopidogrel therapy after PTCA+IR as well as after PTCA significantly reduces
cell proliferation in the vascular lesion. This antiproliferative effect, in addition to the
known antithrombotic effect may explain the long-term reduction in MACE observed in
clinical studies.
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877-1 Duplex Outcomes of the CryoVascular Peripheral 
Balloon Catheter System Safety Registry
Michael Jaff, Vascular Ultrasound Core Laboratory, Morristown, NJ
Background: A novel angioplasty system that uses nitrous oxide (N2O) to inflate the bal-
loon has been developed. The dilation balloon has a target surface temperature of –
10°C.In vitro and in vivo preclinical studies and a number of human clinical cases have
demonstrated this device to be safe and effective for an intended use of PTA of stenotic
lesions in superficial femoral arteries (SFA) and popliteal arteries. The CryoVascular
Safety Registry was designed to demonstrate the safety and effectiveness of the Cry-
oVascular Peripheral Balloon Catheter System in the treatment of femoropopliteal
stenoses. Lower extremity arterial Duplex was used to assess acute procedural out-
comes, as well as maintenance of blood flow at three and nine months post-intervention.
Methods: This FDA-approved study is a non-randomized, multicenter registry of patients
with stenotic and occluded lesions in SFA and popliteal arteries. Results of percutaneous
interventional treatment using the CryoVascular System device were assessed for acute
outcomes, and three-, and nine-month clinical outcomes. This trial was designed to enroll
100 patients, with lesion lengths <10 cm.
Results: A total of 102 patients have been enrolled at 16 sites. The acute procedural
success rate (defined as the ability to achieve <30% residual angiographic stenosis by
visual estimate and <50% residual stenosis by Duplex with antegrade flow to the target
vessel) is 94% (96/102). At the time of the annual meeting, three- and nine-month target
lesion patency as determined by lower extremity arterial Duplex will be reported for all
subjects.
Conclusion: The new angioplasty system safely dilates stenotic and occluded lesions in
the SFA and popliteal arteries with optimal acute results. Nine-month Duplex data may
suggest improved patency in treated vessels.
10:45 a.m.
877-2 Endovascular Gamma Radiation Therapy Inhibits 
Recurrence in Restenotic Lesions of the 
Femoropopliteal Artery: The Vienna Experience
Roswitha M. Wolfram, Erich Minar, University of Vienna, General Hospital Vienna, 
Vienna, Austria
Background: Intracoronary gamma radiation therapy efficiently improves freedom from
recurrent disease in patients with restenosis. This retrospective analysis was designed to
evaluate the efficacy of the gamma emitter 192Ir for the prevention of recurrent re-steno-
sis in the femoropopliteal arteries in patients treated for restenotic lesions.
Methods and Results: A total of 197 patients, treated with either radiation (N=100) or pla-
cebo therapy (N=97), for de-novo or recurrent disease, were retrospectively analyzed.
Sixty-six patients with de-novo-, and 34 patients with recurrent lesions were treated with
gamma radiation. The outcomes of those patients were compared to outcomes of 67
patients with de-novo-, and 30 patients with recurrent lesions treated with percutaneous
transluminal angioplasty (PTA) alone. At 6-, and 12- months there was no difference for
the incidence of restenosis in the de-novo group. In patients initially treated for recur-
rence, however, 6-, and 12-months restenosis rates were significantly lower in the radia-
tion versus the PTA alone group (6-months: 20.7% versus.
66.7%; p < 0.001; 12-months: 26.5% vs. 70.0%; p < 0.001).
Conclusion: The combined therapy of PTA and gamma radiation with 192 Ir, for patients
with recurrent disease in the femoropopliteal arteries results in significant reduction of
restenosis at 6-and 12-months, but does not impact on restenosis in patients with de-
novo lesions.
11:00 a.m.
877-3 Effect of Percutaneous Transluminal Renal Artery 
Angioplasty With Stenting on Renal Function in 
Patients With Atherosclerotic Renal Artery Stenosis
Johan D. Aasbo, David S. Bromet, Roy P. Venzon, Stamatis Dimitropoulos, Martha Gulati, 
Clifford J. Kavinsky, Gary L. Schaer, Jeffrey R. Snell, Rush University Medical Center, 
Chicago, IL
Background: Atherosclerotic renal artery stenosis (ARAS) can lead to renal failure. Per-
cutaneous transluminal renal artery angioplasty with stent placement (PTRA-S) is used
to treat ARAS. Whether PTRA-S slows, stops or reverses the deterioration of renal func-
tion remains controversial. A retrospective review of 80 consecutive patients with ARAS
who underwent PTRA-S at our institution was performed to determine the effect of
PTRA-S on renal function.
Methods: All patients with ARAS who underwent PTRA-S at our institution from 7/97 to
7/02 were included in our review. Serum creatinine (SCr) levels were followed for 4 years
(2 years prior to and 2 years post PTRA-S). 1/SCr was used to approximate renal func-
tion. Linear regression analysis was done to determine the best-fit slope of renal function
over time.
Results: 98 PTRA-S procedures were performed on 80 patients with ARAS. In the 24
months prior to intervention, there was a statistically significant decline of renal function:
slope of -0.005 [P=0.005, 95% CI (-0.007, -0.003)]. Post intervention renal function signif-
icantly improved: slope of +0.0024 [P=0.019, 95% CI( 0.001, 0.004)]. This reversal of the
decline of renal function was sustained over the two years post intervention.
Conclusion: This study demonstrates that PTRA-S reverses the decline in renal function
seen in patients with ARAS. These findings have important clinical implications. 
